AT-406 (SM-406): Orally Bioavailable IAP Inhibitor for Precision Apoptosis Pathway Modulation

Executive Summary:
AT-406 (SM-406) is a small molecule antagonist of inhibitor of apoptosis proteins (IAPs), demonstrating potent binding to XIAP, cIAP1, and cIAP2 with low nanomolar affinity (APExBIO; product page). It induces rapid cIAP1 degradation and activates caspase-dependent apoptosis in a range of cancer cell lines (Sun et al., 2012, DOI). AT-406 exhibits oral bioavailability and significant antitumor efficacy in mouse xenograft models of ovarian and breast cancer (Lu et al., 2011, DOI). It sensitizes ovarian cancer cells to carboplatin, supporting combinatorial therapeutic approaches (AT-406.com: Ovarian Cancer). Clinical tolerability up to 900 mg orally has been established (APExBIO; product dossier).

Biological Rationale

Inhibitor of apoptosis proteins (IAPs) are a conserved family of proteins that suppress caspase activity and regulate programmed cell death (apoptosis), cell cycle progression, and signal transduction. Key human IAPs include XIAP, cIAP1, and cIAP2. These proteins inhibit caspases 3, 7, and 9 via their BIR (baculoviral IAP repeat) domains (Yang et al., 2024, Nature Communications). Dysregulation of IAP expression leads to impaired apoptosis, contributing to cancer cell survival, chemoresistance, and evasion of immune surveillance. Overexpression of XIAP and cIAPs is frequently observed in human malignancies, including ovarian and breast cancers (Sun et al., 2012). Targeting IAPs restores apoptosis competency, sensitizes tumor cells to cytotoxic agents, and is a validated anti-cancer strategy.

Mechanism of Action of AT-406 (SM-406)

AT-406 (SM-406) is a non-peptidomimetic, orally bioavailable small molecule that antagonizes multiple IAPs by binding to the BIR3 domain of XIAP (Ki = 66.4 nM), cIAP1 (Ki = 1.9 nM), and cIAP2 (Ki = 5.1 nM) (APExBIO). This binding inhibits the suppression of caspase 3, 7, and 9, promoting the activation of intrinsic and extrinsic apoptosis pathways. Upon binding, AT-406 induces ubiquitin-mediated proteasomal degradation of cIAP1, leading to formation of death-inducing signaling complexes (DISC) and caspase activation (Lu et al., 2011, DOI). This effect is rapid and dose-dependent in cell-based assays. The compound's mechanism complements recent structural findings on DED domain assembly in FADD-procaspase-8-cFLIP complexes that orchestrate apoptotic and necroptotic signaling (Yang et al., 2024), as AT-406 modulates upstream apoptotic checkpoints by neutralizing IAP-mediated caspase inhibition.

Evidence & Benchmarks

• AT-406 binds XIAP (BIR3) with Ki = 66.4 nM, cIAP1 with Ki = 1.9 nM, and cIAP2 with Ki = 5.1 nM, measured by fluorescence polarization and competitive binding assays (APExBIO).
• Induces rapid, dose-dependent degradation of cIAP1 protein in human cancer cell lines within 2–4 hours at 0.1–3 μM (Lu et al., 2011).
• Restores caspase 3/7/9 activity in IAP-overexpressing cells, activating both intrinsic and extrinsic apoptosis pathways (Yang et al., 2024).
• Displays in vitro IC50 values of 0.05–0.5 μg/mL in human ovarian cancer cell lines (A2780, OVCAR3) (APExBIO).
• Sensitizes ovarian cancer cells to carboplatin; combined treatment reduces cell viability more than monotherapy (synergy index <1) (AT-406.com).
• Oral bioavailability demonstrated in rodent and primate models; plasma half-life supports once-daily dosing (Lu et al., 2011).
• Inhibits tumor growth and prolongs survival in mouse xenograft models of ovarian and breast cancer; tumor regression observed at 10–30 mg/kg oral dosing (Lu et al., 2011).
• Clinically well-tolerated up to 900 mg orally in advanced cancer patients; dose-limiting toxicities are infrequent (APExBIO).

This article extends the mechanistic and translational focus of AT-406 (SM-406): Decoding IAP Inhibition and Apoptosis Research by directly integrating new structural insights on DED assembly and mapping them to AT-406's IAP-targeting mechanism. For a practical overview of preclinical benchmarks, see AT-406 (SM-406): Orally Bioavailable IAP Inhibitor for Cancer Research; this article provides updated clinical tolerability and workflow integration data.

Applications, Limits & Misconceptions

• Preclinical studies: Apoptosis modulation, validation of IAP function in cancer biology, and screening for IAP-dependent phenotypes.
• Translational models: Sensitization assays in ovarian and breast cancer cell lines (A2780, OVCAR3, MDA-MB-231), often in combination with platinum-based chemotherapy.
• In vivo efficacy: Xenograft models in immunodeficient mice for tumor growth inhibition, survival analysis, and pharmacokinetic studies.
• Clinical research: Early-phase studies in advanced solid tumors; dose-escalation to assess safety and pharmacodynamics.

Common Pitfalls or Misconceptions

• AT-406 is not effective in tumor models lacking IAP overexpression—sensitivity relies on baseline IAP activity.
• The compound does not induce apoptosis in normal, non-transformed cells at standard research concentrations (0.1–3 μM).
• AT-406 is not water-soluble; use DMSO or ethanol for in vitro stock solutions.
• Prolonged solution storage at room temperature degrades activity; fresh aliquots at -20°C are recommended.
• AT-406 is not a direct caspase activator; it relieves IAP-mediated caspase inhibition, requiring upstream apoptotic signals.

Workflow Integration & Parameters

AT-406 (SM-406, A3019) is supplied as a solid by APExBIO and should be stored at -20°C. It is soluble at ≥27.65 mg/mL in DMSO and ethanol, but insoluble in water. For cell-based assays, prepare a 10 mM DMSO stock and dilute to 0.1–3 μM in culture media for 24-hour treatments. For in vivo studies, oral dosing (10–30 mg/kg) in suitable vehicles has been validated (Lu et al., 2011).

Experimental endpoints include caspase activation (fluorometric or immunoblot), cell viability (MTT, CellTiter-Glo), and markers of apoptosis (Annexin V, cleaved PARP). For combinatorial studies, time-staggered addition with carboplatin or other chemotherapeutics is recommended to assess synergy.

Consult the AT-406 (SM-406) product page for detailed handling and safety notes. For advanced applications and CRISPR-based mechanistic studies, see AT-406 (SM-406): Advancing IAP Inhibition for Precision Apoptosis Research, which this article updates by providing latest clinical and workflow data.

Conclusion & Outlook

AT-406 (SM-406) is a well-characterized, orally bioavailable IAP inhibitor that enables precise modulation of apoptosis pathways in cancer cells. It exhibits robust activity in preclinical models and is supported by structural and mechanistic evidence from recent studies (Yang et al., 2024). The A3019 reagent expands experimental options for apoptosis research and combinatorial oncology strategies. Future directions include integration with genetic screens for apoptosis susceptibility and clinical investigations in IAP-driven malignancies.